Tianshili Holding Group Co., Ltd

Tianshili group is a high-tech multinational enterprise group, which takes big health industry as the main line, biomedical industry as the core, health products, functional food and other health industries as well as health management and service industry as the two wings.

Established in 1994, Tianshili group always adheres to the corporate philosophy of "pursuing the unity of man and nature, improving the quality of life", insists on building the first brand of modern Chinese medicine, and constantly promotes the sustained and rapid development of the big health industry.

Based on modern scientific and technological innovation, and guided by component traditional Chinese medicine, TSL has formed a technology platform and advanced manufacturing platform for the industrialization development of component traditional Chinese medicine. We have vigorously promoted the innovation and systematic construction of standardized management, formed a modern Chinese medicine industry chain integrating drug research and development, herbal medicine planting, Chinese medicine extraction, preparation production and marketing, and developed and cultivated a number of modern Chinese medicine product groups with exact curative effect and high market reputation. Among them, the most representative compound Danshen Dripping Pills passed the US FDA II in 2010 Phase II clinical trial.

Tianshili Research Institute consists of Institute of modern traditional Chinese medicine, Institute of chemical medicine, Institute of biological medicine, Institute of pharmacology and toxicology, Institute of pharmaceutical analysis, Institute of food and health products, research center for international regulations and registration, research center for international regulations and registration, pharmaceutical administration center, clinical medicine department, project management department, office, logistics and equipment management department R & D management and service guarantee departments such as scientific research finance.

At present, there are 130 management and technical personnel in Tianshili Research Institute, including 22 doctors and postdoctors and 38 masters. Personnel with medium and senior professional and technical titles account for 65% of the total number of the Institute.

By the end of 2006, Tianshili Research Institute had undertaken 20 national level projects, including 2 key projects in the ninth five year plan, 6 key projects in the tenth five year plan, 3 projects in the 863 plan, 2 industrialization demonstration projects, 2 National 973 projects and 7 other national level projects; 235 invention patents were accepted, 11 invention patents were authorized, and 16 new drug production approvals were approved 7 health food production approval documents and 40 new drug clinical approval documents.

Under the development concept of "Research Institute without walls", through the optimization, integration and reasonable layout of scientific research resources, the research institute is gradually building research platforms and project management platforms for drug synthesis, preparation, analysis, pharmacological screening, clinical, domestic and foreign registration, etc. Through the construction of research platform and management platform, timely create valuable innovative products for the sustainable development of innovative enterprises.

Fufang Danshen dripping pills and its series of research have been listed in the top priority project of "modern science and technology industry action plan of traditional Chinese medicine" by the Ministry of science and technology of the people's Republic of China, the national major science and technology achievements promotion project of the ninth five year plan, the national 973 basic research project and the national high-tech industry demonstration project, and won the third prize of national science and technology progress award. Tianshili technology center has been approved as a national enterprise technology center, and the Ministry of personnel has set up a post doctoral research station in Tianshili. The group has been rated as "advanced unit of national spiritual civilization construction" and "Tianjin excellent enterprise"; the "management with modernization of traditional Chinese medicine as the goal" has won the first prize of the eighth national enterprise management modernization innovation achievement; the trademark of Tianshili has been recognized as "well-known trademark" by the State Administration for Industry and commerce.

Tianshili group has been recognized as "the first batch of innovative enterprises" by the Ministry of science and technology of the people's Republic of China, SASAC of the State Council and all China Federation of trade unions. As a national high-tech industrialization demonstration project, Tianshili modern Chinese medicine industrial park won the national ten-year achievement award of high-tech industrialization in 2008. Tianshili has been rated as "Tianjin excellent enterprise", "Tianjin AAA harmonious enterprise of labor relations" for many years in a row, and has been awarded the honorary titles of "national advanced unit of spiritual civilization construction" and "national advanced unit of creating learning organization" by the state for two years in a row.

In recent years, characteristic chemical drugs and high-end biological drugs have also developed rapidly. The international market-oriented chemical drug production base jointly built with coop group of UK has realized production and export. With thrombolytic agent prourokinase and subunit influenza vaccine as the leading agents, biological drugs have formed a research and development platform and industrial platform combining therapeutic and preventive drugs.

With the help of the technological advantages in the field of biomedicine, and in close combination with the core elements of life such as food and drink, it will expand to the life and health industry. In recent years, the modern Baijiu has been developed with the meticulous efforts of the "state Taiwan" brand. The industrial fields such as bio tea, drinking water, health products, functional foods and so on have been guided by scientific and technological innovation, and based on the development of superior resources, a standardized production capacity and branding marketing have been formed.

Facing the future, Tianshili group will continue to develop and expand the big health industry pattern of "one core with two wings". In order to achieve the goal of "creating health and sharing for all", it is determined to innovate and develop scientifically.